Note 10 - Segment Information

9 Months Ended

Sep. 30, 2025

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

(10)        Segment Information

The Company’s reportable segments are reported in a manner consistent with the way management evaluates the businesses. The results of operations are regularly reviewed by the Company's chief operating decision maker ("CODM"), the Chief Executive Officer. The Company identifies its reportable business segments based on differences in products and services. The accounting policies of the business segments are the same as those described in the summary of significant accounting policies. In order to evaluate each reportable segment's performance, the CODM uses income from operations as a measure of profit and loss. The CODM compares operational performance against management expectations when making decisions regarding allocation of operating and capital resources to each segment.

In 2025, the Company has five reportable segments which include: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Device Products, and Fluorine Products. Information regarding the operations and assets of these reportable business segments is contained in the following table:

	Three months ended September 30,				Nine months ended September 30,
Sale of Product	2025		2024		2025		2024
Theranostics Products	$	1,484,284	$	2,183,197	$	5,176,740	$	6,257,410
Cobalt Products		766,682		814,845		1,517,147		1,641,012
Calibration & Reference Products		961,093		926,402		3,301,673		2,099,713
Medical Device Products		65,757		—		176,476		—
Fluorine Products		—		—		—		—
Total Segments		3,277,816		3,924,444		10,172,036		9,998,135
Corporate revenue		—		—		—		—
Total Consolidated	$	3,277,816	$	3,924,444	$	10,172,036	$	9,998,135

	Three months ended September 30,				Nine months ended September 30,
Depreciation and Amortization	2025		2024		2025		2024
Theranostics Products	$	9,962	$	7,785	$	28,066	$	22,528
Cobalt Products		16,360		13,689		48,722		41,103
Calibration & Reference Products		31,481		30,429		92,841		91,848
Medical Device Products		—		—		—		—
Fluorine Products		26,095		20,345		78,285		78,285
Total Segments		83,898		72,248		247,914		233,764
Corporate depreciation and amortization		16,820		28,541		51,784		67,447
Total Consolidated	$	100,718	$	100,789	$	299,698	$	301,211

	Three months ended September 30,						Nine months ended September 30,
Segment Income (Loss)	2025			2024			2025			2024
Theranostics Products	$	634,625		$	1,289,266		$	2,521,006		$	3,474,120
Cobalt Products		245,837			(51,805	)		571			(18,806	)
Calibration & Reference Products		(99,118	)		39,519			130,058			(328,743	)
Medical Device Products		(187,615	)		(167,451	)		(570,589	)		(279,801	)
Fluorine Products		(76	)		(26,095	)		(22,330	)		(30,941	)
Total Segments		593,653			1,083,434			2,058,716			2,815,829
Corporate loss		(797,254	)		(933,183	)		(2,535,796	)		(3,053,074	)
Net Income	$	(203,601	)	$	150,251		$	(477,080	)	$	(237,245	)

	Three months ended September 30,				Nine months ended September 30,
Expenditures for Segment Assets	2025		2024		2025		2024
Theranostics Products	$	—	$	—	$	50,561	$	146,295
Cobalt Products		—		39,799		12,835		39,799
Calibration & Reference Products		—		—		75,663		49,038
Medical Device Products		64,017		—		92,893		—
Fluorine Products		—		—		—		—
Total Segments		64,017		39,799		231,952		235,132
Corporate purchases		—		4,216		22,439		32,175
Total Consolidated	$	64,017	$	44,015	$	254,391	$	267,307

	September 30,		December 31,
Segment Assets	2025		2024
Theranostics Products	$	1,285,118	$	992,513
Cobalt Products		724,834		167,881
Calibration & Reference Products		2,709,918		2,928,814
Medical Device Products		699,583		553,117
Fluorine Products		4,797,454		4,875,738
Total Segments		10,216,907		9,518,063
Corporate assets		7,629,730		7,642,905
Total Consolidated	$	17,846,637	$	17,160,968